<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02049437</url>
  </required_header>
  <id_info>
    <org_study_id>AIDS 347</org_study_id>
    <secondary_id>IL-6</secondary_id>
    <nct_id>NCT02049437</nct_id>
  </id_info>
  <brief_title>AIDS 347: IL-6 Blockade in Treated HIV Infection</brief_title>
  <acronym>IL-6</acronym>
  <official_title>AIDS 347: IL-6 Blockade in Treated HIV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Western Reserve University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Case Western Reserve University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a phase I/II, double-blind, placebo-controlled, randomized cross-over clinical&#xD;
      trial of tocilizumab (TCZ) or placebo in HIV-infected subjects receiving antiretroviral&#xD;
      therapy with suppressed viral replication and CD4+ T cell count ≥350 and ≤1,000 cells/mm3)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      DESIGN The study is a phase I/II, double-blind, placebo-controlled, randomized cross-over&#xD;
      clinical trial of tocilizumab (TCZ) or placebo in HIV-infected subjects receiving&#xD;
      antiretroviral therapy with suppressed viral replication and CD4+ T cell count ≥350 and&#xD;
      ≤1,000 cells/mm3)&#xD;
&#xD;
      DURATION 40 weeks during cross-over treatment periods total per subject.&#xD;
&#xD;
      SAMPLE SIZE 30 subjects with complete data up to week 30. Up to 36 subjects may be enrolled&#xD;
      in order to achieve an estimated final sample size of 30 participants with complete data up&#xD;
      to week 30.&#xD;
&#xD;
      POPULATION HIV-infected male and female subjects from 18 through 60 years of age receiving&#xD;
      combination antiretroviral therapy (ART) without changes in the 24 weeks prior to enrollment&#xD;
      (changes for reasons other than virologic failure allowed up to 8 weeks prior to enrollment),&#xD;
      with a suppressed plasma HIV RNA (&lt;200 copies/mL, one blip up to &lt;1,000 copies/mL permitted)&#xD;
      for at least 96 weeks and a CD4+ T-cell count ≥350 and ≤1,000 cells/mm3 at the time of study&#xD;
      enrollment.&#xD;
&#xD;
      REGIMEN Subjects will be randomized 1:1 to one of the following arms:&#xD;
&#xD;
      ARM A: TCZ, 4 mg/Kg by IV infusion over 60 minutes (not to exceed 400 mg) once at study&#xD;
      entry, followed by TCZ, 8 mg/Kg by IV infusion over 60 minutes (not to exceed 800 mg) at&#xD;
      weeks 4, and 8 and THEN placebo by IV infusion at weeks 20, 24, and 28.&#xD;
&#xD;
      ARM B: Placebo by IV infusion at study entry followed by placebo by IV infusion at weeks 4&#xD;
      and 8, and THEN TCZ, 4 mg/Kg (not to exceed 400 mg) by IV infusion over 60 minutes once at&#xD;
      week 24, followed by TCZ, 8 mg/Kg (not to exceed 800 mg) by IV infusion over 60 minutes at&#xD;
      weeks 24 and 28.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">September 11, 2017</completion_date>
  <primary_completion_date type="Actual">September 11, 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Grade 2 or Greater AEs</measure>
    <time_frame>30 weeks</time_frame>
    <description>The number and percentage of participants experiencing at least one grade ≥2 clinical or laboratory adverse event related to study treatment during each period (0 to 10 weeks for Period 1 or 20 to 30 weeks for Period 2).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum C-reactive Protein Change Between Beginning and End of Treatment Period</measure>
    <time_frame>study entry - 10 weeks; 20 weeks - 30 weeks</time_frame>
    <description>The primary analysis of the two co-primary (CRP and T cell cycling) endpoints will specifically focus on the changes from study entry to week 10 and from week 20 to week 30.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Proportion of Central Memory T Cells Expressing Ki67 Between Beginning and End of Treatment Period</measure>
    <time_frame>study entry - 10 weeks; 20 weeks - 30 weeks</time_frame>
    <description>The primary analysis of the two co-primary (CRP and T cell cycling) endpoints will specifically focus on the changes from study entry to week 10 and from week 20 to week 30.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Arm A: TCZ, then placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ARM A: TCZ, 4 mg/Kg by IV infusion over 60 minutes (not to exceed 400 mg) once at study entry, followed by TCZ, 8 mg/Kg by IV infusion over 60 minutes (not to exceed 800 mg) at weeks 4 and 8, and THEN placebo by IV infusion at weeks 20, 24, and 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Placebo, then TCZ</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>ARM B: Placebo by IV infusion at study entry followed by placebo by IV infusion at weeks 4 and 8, and THEN TCZ, 4 mg/Kg (not to exceed 400 mg) by IV infusion over 60 minutes once at week 20, followed by TCZ, 8 mg/Kg (not to exceed 800 mg) by IV infusion over 60 minutes at weeks 24 and 28.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tocilizumab</intervention_name>
    <description>Subjects will be randomized 1:1 to one of the following arms:&#xD;
ARM A: TCZ, 4 mg/Kg by IV infusion over 60 minutes (not to exceed 400 mg) once at study entry, followed by TCZ, 8 mg/Kg by IV infusion over 60 minutes (not to exceed 800 mg) at weeks 4 and 8, and THEN placebo by IV infusion at weeks 20, 24, and 28.&#xD;
ARM B: Placebo by IV infusion at study entry followed by placebo by IV infusion at weeks 4 and 8, and THEN TCZ, 4 mg/Kg (not to exceed 400 mg) by IV infusion over 60 minutes once at week 20, followed by TCZ, 8 mg/Kg (not to exceed 800 mg) by IV infusion over 60 minutes at weeks 24 and 28.</description>
    <arm_group_label>Arm A: TCZ, then placebo</arm_group_label>
    <arm_group_label>Arm B: Placebo, then TCZ</arm_group_label>
    <other_name>TCZ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will be randomized 1:1 to one of the following arms:&#xD;
ARM A: TCZ, 4 mg/Kg by IV infusion over 60 minutes (not to exceed 400 mg) once at study entry, followed by TCZ, 8 mg/Kg by IV infusion over 60 minutes (not to exceed 800 mg) at weeks 4 aned 8, and THEN placebo by IV infusion at weeks 20, 24, and 28.&#xD;
ARM B: Placebo by IV infusion at study entry followed by placebo by IV infusion at weeks 4 and 8, and THEN TCZ, 4 mg/Kg (not to exceed 400 mg) by IV infusion over 60 minutes once at week 20, followed by TCZ, 8 mg/Kg (not to exceed 800 mg) by IV infusion over 60 minutes at weeks 24 and 28.</description>
    <arm_group_label>Arm A: TCZ, then placebo</arm_group_label>
    <arm_group_label>Arm B: Placebo, then TCZ</arm_group_label>
    <other_name>Normal saline for infusion</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        4.1.1 Men and women age 18-60 years.&#xD;
&#xD;
        4.1.2 Ability and willingness to communicate in English or Spanish&#xD;
&#xD;
        4.1.3 Ability and willingness of subject to provide informed consent.&#xD;
&#xD;
        4.1.4 Ability and willingness to provide adequate locator information.&#xD;
&#xD;
        4.1.5 HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or&#xD;
        chemiluminescence immunoassay (E/CIA) test at any time before study entry and confirmed by&#xD;
        a licensed Western blot, a second antibody test by a method other than rapid HIV or E/CIA;&#xD;
        HIV-1 antigen; or plasma HIV-1 RNA viral load.&#xD;
&#xD;
        4.1.6 Receiving a stable antiretroviral regimen consisting of 3 or more drugs belonging to&#xD;
        two or more classes, one of which must be a protease inhibitor, an integrase inhibitor, or&#xD;
        a non-nucleoside reverse transcriptase inhibitor, without any changes due to virologic&#xD;
        failure in the past 24 weeks, and with no plans to change antiretroviral regimen in the 40&#xD;
        weeks following enrollment. If the regimen includes a protease inhibitor, ritonavir or an&#xD;
        approved boosting agent known to increase trough levels of the protease inhibitor by at&#xD;
        least 50% must also be a part of the regimen.&#xD;
&#xD;
        NOTE A: Changes to the antiretroviral regimen 8 weeks or more prior to enrollment are&#xD;
        allowed if the plasma HIV RNA was &lt;50 copies/mL at the time of the change, the reason for&#xD;
        the change was not suspicion or documentation of virologic failure, and all other criteria&#xD;
        for virologic control, as outlined in criterion 4.1.9 below, are met.&#xD;
&#xD;
        NOTE B: For the purposes of this protocol, &quot;a change due to virologic failure&quot; is defined&#xD;
        as any of the following events or combinations thereof happening in a patient who is&#xD;
        receiving uninterrupted combination antiretroviral therapy including at least three agents&#xD;
        belonging to at least two classes: a) plasma HIV RNA is &gt;200 copies/mL on two or more&#xD;
        consecutive occasions; b) the treating physician determines that any given plasma HIV RNA&#xD;
        value is indicative or suggestive of virologic failure, and recommends that the patient's&#xD;
        regimen be modified as a result; c) a genotypic or phenotypic antiretroviral resistance&#xD;
        test identifies the presence of resistance to any component of a patient's regimen that was&#xD;
        not present before, and a physician recommends that the patient's regimen be modified as a&#xD;
        result.&#xD;
&#xD;
        4.1.7 For subjects who have a positive HBcAb only:&#xD;
&#xD;
        • An antiretroviral regimen containing one or more of the following medications:&#xD;
        lamivudine, emtricitabine, or tenofovir.&#xD;
&#xD;
        4.1.8 Screening CD4+ T-cell count ≥350 cells/mm3 but ≤1,000 cells/mm3 performed in a&#xD;
        laboratory that has a Clinical Laboratory Improvement Amendments (CLIA) certification or&#xD;
        its equivalent.&#xD;
&#xD;
        4.1.9 HIV-1 RNA &lt;200 copies/mL at every time a plasma HIV RNA has been obtained, but no&#xD;
        fewer than twice, in the 96 weeks prior to enrollment.&#xD;
&#xD;
        NOTE: One plasma HIV RNA above 200 copies/mL but lower than 1,000 copies in the 96 weeks&#xD;
        prior to enrollment is permissible if flanked by two measurements that are both below 200&#xD;
        copies. The HIV-1 RNA at screening must be &lt;50 copies/mL.&#xD;
&#xD;
        4.1.10 The following laboratory values obtained within 60 days prior to entry:&#xD;
&#xD;
          -  Hgb ≥10 g/dL&#xD;
&#xD;
          -  Platelet count &gt;100,000/mm3&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) ≥2,000 cells/mm3&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) [serum glutamic oxaloacetic transaminase (SGOT)]&#xD;
             &lt;1.5x ULN&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) [serum glutamic pyruvic transaminase (SGPT)] &lt;1.5x ULN&#xD;
&#xD;
          -  For subjects who consent to undergo rectal tissue sampling only: International&#xD;
             normalized ratio (INR) &lt; 1.7&#xD;
&#xD;
          -  Total bilirubin &lt;3.0 mg/dL, EXCEPT for subjects receiving atazanavir&#xD;
&#xD;
          -  For subjects receiving atazanavir: Direct bilirubin ≤1.0 mg/dL&#xD;
&#xD;
          -  Calculated GFR ≥60 mL/min/1.73m2&#xD;
&#xD;
        4.1.11 Female subjects of reproductive potential must have a negative serum or urine&#xD;
        pregnancy test at study entry and must affirm that they do not intend to become pregnant&#xD;
        for the duration of the study.&#xD;
&#xD;
        NOTE: For the purposes of this protocol, a female subject of reproductive potential is&#xD;
        defined as one who has reached menarche, has not been post-menopausal for at least 24&#xD;
        consecutive months (i.e., has had menses within the preceding 24 months), and has not&#xD;
        undergone surgical sterilization (e.g., hysterectomy, tubal ligation, or bilateral&#xD;
        oophorectomy).&#xD;
&#xD;
        4.1.12 Female subjects of reproductive potential participating in sexual activity that&#xD;
        could lead to pregnancy must agree to use at least one of the following forms of birth&#xD;
        control for at least 30 days prior to study entry through 30 days after the final study&#xD;
        visit:&#xD;
&#xD;
          -  Condoms (male or female) with or without a spermicidal agent&#xD;
&#xD;
          -  Diaphragm or cervical cap with spermicide&#xD;
&#xD;
        PLUS at least one of the following:&#xD;
&#xD;
          -  An FDA-approved copper intrauterine device (IUD), e.g. ParaGard®, or an FDA-approved&#xD;
             hormone-releasing IUD, e.g. Mirena®&#xD;
&#xD;
          -  An FDA-approved transdermal hormonal contraceptive, e.g. Ortho-Evra®&#xD;
&#xD;
          -  An FDA-approved injectable hormonal contraceptive, e.g. Depo-Provera®&#xD;
&#xD;
          -  An FDA-approved hormonal contraceptive in vaginal ring form, e.g. NuvaRing®&#xD;
&#xD;
          -  An FDA-approved implantable hormonal contraceptive, e.g. Implanon® or Jadelle®&#xD;
&#xD;
        NOTE A: Oral hormonal contraceptives, either combined or progestin-only, are not acceptable&#xD;
        as a second contraceptive method.&#xD;
&#xD;
        NOTE B: Women of reproductive potential who are using a hormonal contraceptive not included&#xD;
        above may consider switching their contraceptive to one of the approved forms, but will be&#xD;
        required to do so in consultation with their primary healthcare providers. Study&#xD;
        investigators will not prescribe or recommend a specific form of contraception to study&#xD;
        participants. The study will not cover the costs of contraceptives.&#xD;
&#xD;
        4.1.13 Female subjects who are not of reproductive potential [i.e., women who have been&#xD;
        post-menopausal for at least 24 consecutive months or women who have undergone surgical&#xD;
        sterilization (e.g., hysterectomy, tubal ligation, or bilateral oophorectomy)] are eligible&#xD;
        without requiring the use of a contraceptive. Acceptable documentation of sterilization,&#xD;
        other contraception methods, menopause and reproductive potential is patient-reported&#xD;
        history at any time prior to screening.&#xD;
&#xD;
        4.1.14 Subjects must be determined by the investigators to have at least one fully active&#xD;
        regimen available to them other than the regimen they are receiving at study entry. The&#xD;
        determination of whether or not an alternative regimen is available must take into account&#xD;
        both the subject's antiretroviral history and any previously obtained resistance testing. A&#xD;
        valid alternative regimen must meet the recommendations for an active regimen outlined in&#xD;
        the current DHHS guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults&#xD;
        and Adolescents (93).&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        4.2.1 History of one of the following opportunistic infections at any time in the past, as&#xD;
        demonstrated by either a patient-reported or physician-documented diagnosis AND the&#xD;
        initiation of specific treatment if applicable:&#xD;
&#xD;
          -  Tuberculosis, pulmonary or extrapulmonary&#xD;
&#xD;
          -  Non-tuberculous mycobacterial infection, disseminated or extrapulmonary&#xD;
&#xD;
          -  Pneumocystis jirovecii pneumonia&#xD;
&#xD;
          -  Coccidioidomycosis, disseminated or extrapulmonary&#xD;
&#xD;
          -  Cryptococcosis, extrapulmonary&#xD;
&#xD;
          -  Cryptosporidiosis or isosporiasis, chronic intestinal (greater than 1 month's&#xD;
             duration)&#xD;
&#xD;
          -  Cytomegalovirus disease (other than liver, spleen, or lymph nodes) and including&#xD;
             retinitis with loss of vision&#xD;
&#xD;
          -  Histoplasmosis, disseminated or extrapulmonary&#xD;
&#xD;
          -  Kaposi's sarcoma&#xD;
&#xD;
          -  Lymphoma, Burkitt's or immunoblastic, regardless of anatomical location&#xD;
&#xD;
          -  Lymphoma, primary of brain&#xD;
&#xD;
          -  Progressive multifocal leukoencephalopathy&#xD;
&#xD;
          -  Toxoplasmosis of brain&#xD;
&#xD;
        4.2.2 Latent tuberculosis infection, defined as a positive or borderline FDA-approved&#xD;
        interferon-gamma release assay (IGRA).&#xD;
&#xD;
        4.2.3 Pregnant or breastfeeding.&#xD;
&#xD;
        4.2.4 Active local or systemic infection (defined as requiring systemic antibiotics or&#xD;
        other medical or surgical treatment) at the time of enrollment.&#xD;
&#xD;
        4.2.5 Use of systemic cancer chemotherapy or radiation therapy, immunosuppressive or&#xD;
        immunomodulatory therapy (e.g., interferons, tumor necrosis factor antagonists,&#xD;
        interleukins) or any investigational therapy within 90 days prior to study entry or&#xD;
        continued indication for such medications. A list of prohibited study medications is&#xD;
        provided in appendix 1 of the Manual of Operations (MOPS).&#xD;
&#xD;
        NOTE A: Use of inhaled or nasal steroids, the equivalent of 10 mg of prednisone or less per&#xD;
        day or a less than 2-week course of steroids are not exclusionary.&#xD;
&#xD;
        NOTE B: A single course of 1% hydrocortisone cream or equivalent applied up to 3 times a&#xD;
        day to &lt;10 square inches area for &lt;2 weeks is permitted. The investigators will determine&#xD;
        if other forms of limited, short-term topical steroid use are expected to interfere&#xD;
        significantly with the study objectives and are therefore exclusionary.&#xD;
&#xD;
        4.2.6 Receipt of a live attenuated vaccine within 30 days prior to study entry or expected&#xD;
        need for such vaccines at any time during and for 30 days after the study.&#xD;
&#xD;
        4.2.7 Known allergy/sensitivity or any hypersensitivity to components of the study drug or&#xD;
        its formulation.&#xD;
&#xD;
        4.2.8 Active drug or alcohol use or dependence that, in the opinion of the site&#xD;
        investigator, would interfere with adherence to study requirements.&#xD;
&#xD;
        4.2.9 Serious illness requiring systemic treatment and/or hospitalization within 45 days&#xD;
        prior to study entry.&#xD;
&#xD;
        4.2.11 Known cirrhosis or severe liver disease (e.g., ascites, encephalopathy, history of&#xD;
        variceal bleeding).&#xD;
&#xD;
        4.2.12 Active hepatitis B (positive HBsAg, HBV DNA, or HBeAg) or hepatitis C (positive HCV&#xD;
        antibody and positive HCV RNA in plasma) documented at the screening visit.&#xD;
&#xD;
        NOTE A: For purposes of documenting hepatitis B status, an HBsAg or HBV DNA obtained in the&#xD;
        6 months prior to and up to the date of the screening visit is acceptable EXCEPT for&#xD;
        subjects with a positive HBcAb at screening (see Note B). A negative HBeAg during the same&#xD;
        period in the absence of an HBsAg or HBV DNA is not sufficient evidence of HBV-negative&#xD;
        status. If a clinically obtained test is not available at screening, an HBsAg will be drawn&#xD;
        together with other evaluations at this visit.&#xD;
&#xD;
        NOTE B: For subjects with a positive HBcAb at screening, an HBV DNA below the limit of&#xD;
        quantification at any time from screening to study entry is required.&#xD;
&#xD;
        NOTE C: For purposes of documenting HCV status, a negative HCV antibody obtained in the 6&#xD;
        months prior to and up to the date of the screening visit is sufficient. For any subject&#xD;
        with a positive HCV antibody, an HCV RNA measurement is required.&#xD;
&#xD;
        4.2.13 History of diverticulitis, intestinal perforation, distal intestinal obstruction, or&#xD;
        lower gastrointestinal bleeding.&#xD;
&#xD;
        4.2.14 An antiretroviral regimen containing maraviroc at study entry. 4.215 History of a&#xD;
        demyelinating disorder such as multiple sclerosis or chronic demyelinating polyneuropathy&#xD;
        at any time in the past.&#xD;
&#xD;
        4.2.16 A trough level of any protease inhibitor (other than a boosting dose of ritonavir)&#xD;
        or non-nucleoside reverse transcriptase inhibitor included in the subject's antiretroviral&#xD;
        regimen at screening that is below the lower limit of the steady-state trough level range&#xD;
        observed in published studies, according to Table 2, below.&#xD;
&#xD;
        Table 2: Cutoffs of selected antiretroviral trough levels Drug Lower limit of range (levels&#xD;
        below this at screening are exclusionary) Efavirenz(94) 1 µg/mL Nevirapine(94) 3 µg/mL&#xD;
        Etravirine(95) 75 ng/mL Rilpivirine(96) 4 ng/mL Atazanavir/r(94) 0.15 µg/mL Darunavir/r(96)&#xD;
        1036 ng/mL Lopinavir/r(94)&#xD;
&#xD;
        1 µg/mL Amprenavir(94) 0.4 µg/mL Fosamprenavir/r(94) 0.4 µg/mL Indinavir/r(94) 0.1 µg/mL&#xD;
        Saquinavir SGC/r(94) 0.1 µg/mL Nelfinavir(94) 0.8 µg/mL&#xD;
&#xD;
        4.2.17 Active malignant disease, other than a resected basal cell carcinoma of the skin.&#xD;
&#xD;
        4.2.18 For subjects who consent to undergo rectal tissue sampling only:&#xD;
&#xD;
          -  History of a bleeding diathesis of any kind, or contraindication for lower GI&#xD;
             endoscopy&#xD;
&#xD;
          -  Major GI tract surgery within 45 days prior to study entry. Minor procedures involving&#xD;
             only the anal canal such as condyloma ablations, hemorrhoidectomy, and anoscopy are&#xD;
             permitted if cleared by the responsible surgeon.&#xD;
&#xD;
          -  Continued need for, or use during the 7 days prior to the scheduled flex-sig&#xD;
             procedure, of the following medications:&#xD;
&#xD;
               -  Aspirin, systemic antiplatelet agents, or more than 4 doses of NSAIDs&#xD;
&#xD;
               -  Warfarin, heparin, thrombin inhibitors, factor Xa inhibitors, and systemic&#xD;
                  thromobolytics and fibrinolytics. A list of prohibited medications for the&#xD;
                  flex-sig procedure can be found in the appendix of the MOPS. A bridge course of&#xD;
                  short-acting low-molecular weight heparin within the 7-day pre-procedure window&#xD;
                  in patients receiving a chronic systemic anticoagulant who can be safely&#xD;
                  maintained off anticoagulation for several days is permitted if cleared by the&#xD;
                  subject's primary healthcare provider and the UHCMC Digestive Health Institute.&#xD;
&#xD;
          -  Abnormalities of the colorectal mucosa, or significant colorectal symptoms, which in&#xD;
             the opinion of the clinician represent a contraindication to biopsy (including but not&#xD;
             limited to presence of any unresolved injury, infectious or inflammatory condition of&#xD;
             the local mucosa)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benigno Rodriguez, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Case Western Reserve University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Lederman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Case Western Reserve University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Case Clinical Research Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>January 28, 2014</study_first_submitted>
  <study_first_submitted_qc>January 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2014</study_first_posted>
  <results_first_submitted>October 28, 2020</results_first_submitted>
  <results_first_submitted_qc>November 19, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 17, 2020</results_first_posted>
  <last_update_submitted>December 15, 2020</last_update_submitted>
  <last_update_submitted_qc>December 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Case Western Reserve University</investigator_affiliation>
    <investigator_full_name>Cheryl Smith</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Immune failure</keyword>
  <keyword>Tocilizumab</keyword>
  <keyword>ACTEMRA</keyword>
  <keyword>Antiretroviral therapy</keyword>
  <keyword>HAART</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 12, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/37/NCT02049437/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm A: TCZ, Then Placebo</title>
          <description>ARM A: TCZ, 4 mg/Kg by IV infusion over 60 minutes (not to exceed 400 mg) once at study entry, followed by TCZ, 8 mg/Kg by IV infusion over 60 minutes (not to exceed 800 mg) at weeks 4 and 8, and THEN placebo by IV infusion at weeks 20, 24, and 28.</description>
        </group>
        <group group_id="P2">
          <title>Arm B: Placebo, Then TCZ</title>
          <description>ARM B: Placebo by IV infusion at study entry, followed by placebo by IV infusion at weeks 4 and 8, and THEN TCZ, 4 mg/Kg (not to exceed 400 mg) by IV infusion over 60 min once at week 20, followed by TCZ, 8 mg/Kg (not to exceed 800 mg) by IV infusion over 60 min at weeks 24 and 28.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="16">Dropout due to low trough levels</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm A: TCZ, Then Placebo</title>
          <description>ARM A: TCZ, 4 mg/Kg by IV infusion over 60 minutes (not to exceed 400 mg) once at study entry, followed by TCZ, 8 mg/Kg by IV infusion over 60 minutes (not to exceed 800 mg) at weeks 4 and 8, and THEN placebo by IV infusion at weeks 20, 24, and 28.</description>
        </group>
        <group group_id="B2">
          <title>Arm B: Placebo, Then TCZ</title>
          <description>ARM B: Placebo by IV infusion at study entry followed by placebo by IV infusion at weeks 4 and 8, and THEN TCZ, 4 mg/Kg (not to exceed 400 mg) by IV infusion over 60 minutes once at week 20, followed by TCZ, 8 mg/Kg (not to exceed 800 mg) by IV infusion over 60 minutes at weeks 24 and 28.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47" lower_limit="42" upper_limit="53"/>
                    <measurement group_id="B2" value="49" lower_limit="44" upper_limit="54"/>
                    <measurement group_id="B3" value="48" lower_limit="42" upper_limit="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Grade 2 or Greater AEs</title>
        <description>The number and percentage of participants experiencing at least one grade ≥2 clinical or laboratory adverse event related to study treatment during each period (0 to 10 weeks for Period 1 or 20 to 30 weeks for Period 2).</description>
        <time_frame>30 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tocilizumab</title>
            <description>Patients from Arm A that obtained TCZ, 4 mg/kg by IV infusion over 60 min (not to exceed 400 mg) once at study entry, followed by TCZ, 8 mg/kg by IV infusion over 60 min (not to exceed 800 mg) at weeks 4, and 8.&#xD;
Patients from Arm B that obtained TCZ, 4 mg/kg by IV infusion over 60 min (not to exceed 400 mg) once at week 20, followed by TCZ, 8 mg/kg (not to exceed 800 mg) by IV infusion over 60 minutes at weeks 24 and 28 after the first (placebo) interventional period and washout period</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients from Arm A that, after washout period 1, obtained placebo by IV infusion at weeks 20, 24 and 28.&#xD;
Patients from Arm B that obtained placebo by IV infusion at study entry followed by placebo by IV infusion at weeks 4 and 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Grade 2 or Greater AEs</title>
          <description>The number and percentage of participants experiencing at least one grade ≥2 clinical or laboratory adverse event related to study treatment during each period (0 to 10 weeks for Period 1 or 20 to 30 weeks for Period 2).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.07</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>4.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.90</ci_lower_limit>
            <ci_upper_limit>21.83</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum C-reactive Protein Change Between Beginning and End of Treatment Period</title>
        <description>The primary analysis of the two co-primary (CRP and T cell cycling) endpoints will specifically focus on the changes from study entry to week 10 and from week 20 to week 30.</description>
        <time_frame>study entry - 10 weeks; 20 weeks - 30 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tocilizumab</title>
            <description>Patients from Arm A that obtained TCZ, 4 mg/kg by IV infusion over 60 min (not to exceed 400 mg) once at study entry, followed by TCZ, 8 mg/kg by IV infusion over 60 min (not to exceed 800 mg) at weeks 4, and 8.&#xD;
Patients from Arm B that obtained TCZ, 4 mg/kg by IV infusion over 60 min (not to exceed 400 mg) once at week 20, followed by TCZ, 8 mg/kg (not to exceed 800 mg) by IV infusion over 60 minutes at weeks 24 and 28 after the first (placebo) interventional period and washout period</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients from Arm A that, after washout period 1, obtained placebo by IV infusion at weeks 20, 24 and 28.&#xD;
Patients from Arm B that obtained placebo by IV infusion at study entry followed by placebo by IV infusion at weeks 4 and 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum C-reactive Protein Change Between Beginning and End of Treatment Period</title>
          <description>The primary analysis of the two co-primary (CRP and T cell cycling) endpoints will specifically focus on the changes from study entry to week 10 and from week 20 to week 30.</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serum C-reactive protein at either study entry or week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4316" spread="6907"/>
                    <measurement group_id="O2" value="3320" spread="4149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum C-reactive protein at either 10 weeks or 30 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157" spread="183"/>
                    <measurement group_id="O2" value="2256" spread="1928"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2036.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3490.32</ci_lower_limit>
            <ci_upper_limit>-900.62</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Proportion of Central Memory T Cells Expressing Ki67 Between Beginning and End of Treatment Period</title>
        <description>The primary analysis of the two co-primary (CRP and T cell cycling) endpoints will specifically focus on the changes from study entry to week 10 and from week 20 to week 30.</description>
        <time_frame>study entry - 10 weeks; 20 weeks - 30 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tocilizumab</title>
            <description>Patients from Arm A that obtained TCZ, 4 mg/kg by IV infusion over 60 min (not to exceed 400 mg) once at study entry, followed by TCZ, 8 mg/kg by IV infusion over 60 min (not to exceed 800 mg) at weeks 4, and 8.&#xD;
Patients from Arm B that obtained TCZ, 4 mg/kg by IV infusion over 60 min (not to exceed 400 mg) once at week 20, followed by TCZ, 8 mg/kg (not to exceed 800 mg) by IV infusion over 60 minutes at weeks 24 and 28 after the first (placebo) interventional period and washout period</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients from Arm A that, after washout period 1, obtained placebo by IV infusion at weeks 20, 24 and 28.&#xD;
Patients from Arm B that obtained placebo by IV infusion at study entry followed by placebo by IV infusion at weeks 4 and 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Proportion of Central Memory T Cells Expressing Ki67 Between Beginning and End of Treatment Period</title>
          <description>The primary analysis of the two co-primary (CRP and T cell cycling) endpoints will specifically focus on the changes from study entry to week 10 and from week 20 to week 30.</description>
          <units>proportion of central memory T cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>proportion of central memory T cells expressing Ki67 at either study entry or 20 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0689" spread="0.0222"/>
                    <measurement group_id="O2" value="0.0721" spread="0.0293"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>proportion of central memory T cells expressing Ki67 at either 10 weeks or 30 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0685" spread="0.0192"/>
                    <measurement group_id="O2" value="0.0708" spread="0.0222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.77</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.79</ci_lower_limit>
            <ci_upper_limit>0.65</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected over the total length of the trial, 40 weeks.</time_frame>
      <desc>33 patients were at risk for adverse events during the Toculizumab treatment: 17 patients in arm A that started Toculizumab in period 1 + 16 patients in arm B that started Toculizumab in period 2 32 patients were at risk for adverse events during the placebo treatment: 17 patients in arm B that started placebo in period 1 + 15 patients in arm A that started placebo treatment in period 2</desc>
      <group_list>
        <group group_id="E1">
          <title>Tocilizumab</title>
          <description>Patients from Arm A that obtained TCZ, 4 mg/kg by IV infusion over 60 min (not to exceed 400 mg) once at study entry, followed by TCZ, 8 mg/kg by IV infusion over 60 min (not to exceed 800 mg) at weeks 4, and 8.&#xD;
Patients from Arm B that obtained TCZ, 4 mg/kg by IV infusion over 60 min (not to exceed 400 mg) once at week 20, followed by TCZ, 8 mg/kg (not to exceed 800 mg) by IV infusion over 60 minutes at weeks 24 and 28 after the first (placebo) interventional period and washout period</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Patients from Arm A that, after washout period 1, obtained placebo by IV infusion at weeks 20, 24 and 28.&#xD;
Patients from Arm B that obtained placebo by IV infusion at study entry followed by placebo by IV infusion at weeks 4 and 8.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Severe neutropenia</sub_title>
                <description>ANC&lt;500</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Viral gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal blood test</sub_title>
                <counts group_id="E1" events="45" subjects_affected="21" subjects_at_risk="33"/>
                <counts group_id="E2" events="29" subjects_affected="15" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>radius fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acute gout flare</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hidradentitis Suppurativa</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Marijke Frederix, PhD</name_or_title>
      <organization>University Hospitals Cleveland Medical Center</organization>
      <phone>(216) 844-0383</phone>
      <email>marijke.frederix@UHhospitals.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

